- Researchers have developed an experimental implant designed to connect insulin-producing cells directly to the bloodstream while shielding them from immune attack.
- The device is intended as a step towards a bioartificial pancreas for type 1 diabetes, with immediate blood supply being one of its main advantages.
- It showed promise in preclinical work, but it is still far from being a treatment people can access routinely.
One of the biggest problems in cell-based treatments for type 1 diabetes is keeping transplanted insulin-producing cells alive.
Many die early because they do not get an adequate blood supply quickly enough.
Researchers at McGill say they may have found a way round that problem.
They have developed an implant with a pre-formed network of artificial blood vessels.
The idea is to connect insulin-producing cells to the circulation from the start, while also placing them behind a protective barrier that helps reduce immune rejection.
That could make a big difference.
Traditional islet transplantation can work, but donor tissue is scarce and lifelong immunosuppression is often needed.
This new device is designed to use lab-grown cells instead.
That would make supply less dependent on deceased donors.
It also offers a more structured, engineered system rather than simply injecting cells and hoping they settle in.
The researchers describe it as starting to look like a true artificial organ.
That may sound grand, but the concept is straightforward.
Insulin-producing cells need oxygen, nutrients and rapid access to the blood if they are going to function well.
- Continuous glucose monitors improved blood sugar control in people with type 2 diabetes using basal insulin
- Fat tissue blood vessels may play a bigger role in obesity and type 2 diabetes than previously thought
A device that solves those problems while blocking the immune system would address some of the biggest obstacles in the field.
For now, though, this is preclinical work.
It is promising engineering, not a cure that is about to arrive in clinic.
Still, it is one of the more practical attempts to deal with the blood supply problem that has held back cell therapy for type 1 diabetes for years.
